A-1331852
first-in-class, bioavailable BCL-XL inhibitor oral efficacy in xenograft, led to ADC dev. from SBDD of prior BH3 mimetics ACS Med. Chem. Lett., Jul. 5, 2020 AbbVie, North Chicago, IL / Genentech
Molecules of the Month - July 2020
Molecules of the Month
- A-1331852
- dotinurad (FYU-981)
- X-165
- "compound 38a"
- HTL22562
- "compound 23"
- MGS0274
- LXE408
- "compound 2"
- AB680
- "compound 18"
- ETX0282
- "compound 6g"
- EC2629